Risk of COVID-19 infection in patients with NSCLC receiving EGFR-TKI targeted therapy during the first wave in China
NSCLC treatment can be continued for patients who received COVID-19 vaccines, those with higher BMI, and those without comorbidities during the COVID-19 epidemic, but treatment interruption might be required for patients during the active phase of infection.
Authors
- Long Huang (ORCID: https://orcid.org/0000-0002-5372-071X)
- Yanling Yi
- Chen Luo (ORCID: https://orcid.org/0000-0002-2719-244X)
- Peng Huang (ORCID: https://orcid.org/0009-0004-6021-1501)
- Jiali Zhao (ORCID: https://orcid.org/0000-0002-7559-3782)
- Ling-Ming Liao
- Yu Chen (ORCID: https://orcid.org/0000-0003-3610-594X)
Institutions
- Nanchang University (CN)
- Jiangxi Provincial Cancer Hospital (CN)
- Second Affiliated Hospital of Nanchang University (CN)
Publication Details
- Journal
- Journal of International Medical Research
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1177/03000605241281907
- Citations
- 3
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.26
Funders
- Health Commission of Jiangxi Province